TABLE 3.
Procedure characteristics across included studies.
| References | Study arm | Procedure type |
Access |
CM type | |||||
| CA only (%) | CA + PCI (%) | PCI only (%) | CTO (%) | PVI (%) | Radial (%) | Femoral (%) | |||
| Desch et al. (27) | DyeVert | 100 | 0 | 0 | 0 | 0 | 48 | NR | Iomeprol (Imeron 350) Iomeprol (Imeron 350) |
| Control | 100 | 0 | 0 | 0 | 0 | 46 | NR | ||
| Bath et al. (29) | DyeVert | 100 | 0 | 0 | 0 | 0 | NR | NR | NR |
| Control | 100 | 0 | 0 | 0 | 0 | 0 | NR | NR | |
| Briguori et al. (30) | DyeVert | 1 | 99* | NR | 0 | 97 | NR | Iobitridol (Xenetix 350) | |
| Control | 2 | 98* | NR | 0 | 99 | NR | Iobitridol (Xenetix 350) | ||
| Sattar et al. (31) | DyeVert | 0 | 100* | NR | 0 | NR | NR | NR | |
| Control | 0 | 100* | NR | 0 | NR | NR | NR | ||
| Kutschman (32) | Overall | 37 | 63* | 10 | 0 | NR | NR | NR | |
| Kutschman et al. (33) | Overall | 31 | 69* | 9 | 0 | NR | NR | NR | |
| Bunney et al. (34) | DyeVert | 0 | 100* | NR | 0 | NR | NR | NR | |
| Control | 0 | 100* | NR | 0 | NR | NR | NR | ||
| Tajti et al. (35) | DyeVert | 0 | 100* | 100 | 0 | 50 | 95 | Iodixanol (Visipaque) 79.5%; iohexol (Omnipaque) 20.5% | |
| Control | 0 | 100* | 100 | 0 | 19 | 92 | NR | ||
| Zimin et al. (36) | DyeVert | 0 | 87 | 13 | 0 | 0 | 47 | 53 | Iopamidol (Isovue 370) |
| Control | 7 | 93 | 0 | 0 | 0 | 0 | 100 | Iopamidol (Isovue 370) | |
| Sapontis et al. (37) | DyeVert | 77 | 16 | 7 | NR | 0 | NR | NR | Iodixanol 320 52%; iohexol 350 46%; other 2% |
| Corcione et al. (38) | DyeVert | 50 | 10 | 20 | 0 | 20 | 70 | 30 | Iohexol (Omnipaque 350) 50%; iopromide (Ultravist 370) 30%; ioversol (Optiray 350) 20% |
| Gurm et al. (39) | DyeVert | 65 | 26 | 9 | 0 | 0 | 37 | 63 | Iodixanol (Visipaque 320) 55%; iohexol (Omnipaque 350) 18%; iohexol (Omnipaque 300) 14%; iopamidol (Isovue) 7%; iodixanol (Visipaque 270) 6% |
| Turner and Tucker (40) | Overall | 0 | 100* | NR | 0 | NR | NR | NR | |
| Cameron and Espinosa (41) | Overall | 57 | 43* | NR | 0 | NR | NR | NR | |
| Rao (42) | DyeVert | 0 | 0 | 0 | 43 | 100 | 0 | 100 | Iodixanol (Visipaque 320) |
| Amoroso et al. (43) | DyeVert | 54 | 46* | 0 | 0 | 85 | NR | Accupaque 350 35%; Niopam 300 27%; iodixanol (Visipaque 270) 38% |
|
| Bruno et al. (28) | DyeVert | 78 | 22 | 0 | 0 | 0 | NR | NR | Accupaque 350 |
*PCI proportion with or without a diagnostic coronary angiography component was not reported.
Data presented are %.
CA, diagnostic coronary angiography; CM, contrast media; CTO, chronic total occlusion; NR, not reported; PCI, percutaneous coronary intervention; PVI, peripheral vascular intervention.